ABvac40

Evidence outlook · lead readout

NCT03461276 · Mild Cognitive Impairment, Alzheimer Disease

The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.

NCT03461276: The 134-participant trial was randomized, triple-blind, and placebo-controlled, with 62 participants assigned to each Part A group; its primary endpoint was met, with ABvac40 generating significantly higher anti-Aβ40 antibody responses than placebo. Because the primary endpoint measured immunogenicity rather than clinical benefit, the results provide moderate evidence.